Indivior PLC (NASDAQ:INDV) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Indivior PLC (NASDAQ:INDV) have received a consensus rating of “Moderate Buy” from the seven brokerages that are covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $45.1667.

INDV has been the subject of several recent analyst reports. Craig Hallum restated a “buy” rating and issued a $53.00 target price on shares of Indivior in a research note on Tuesday. Zacks Research cut shares of Indivior from a “strong-buy” rating to a “hold” rating in a report on Monday, June 29th. Weiss Ratings upgraded shares of Indivior from a “hold (c)” rating to a “hold (c+)” rating in a research report on Friday, July 24th. Finally, Barclays lowered their price objective on Indivior from $46.00 to $43.00 and set an “overweight” rating on the stock in a report on Wednesday.

Indivior News Summary

Here are the key news stories impacting Indivior this week:

• Positive Sentiment: HC Wainwright raised its Indivior earnings forecasts across 2026–2030. The firm lifted its 2026 EPS estimate to $3.66 from $3.08, raised 2027 EPS to $3.83 from $3.34, and increased 2028–2030 estimates to $3.99, $4.22 and $4.46, respectively. Its quarterly estimates also rose to $0.93 for Q3 2026 and $1.07 for Q4, signaling improved expectations for the company’s operating performance. Indivior analyst estimates
• Positive Sentiment: An insider purchased additional shares. Chief Accounting Officer Woodrow Anderson bought 1,500 shares at an average price of $36.28, increasing his direct holdings by 6.09%. Insider buying can be viewed as a modest vote of confidence in the stock’s valuation and outlook. Insider Buying: Indivior CAO Acquires 1,500 Shares
• Neutral Sentiment: Analyst sentiment remains favorable but not uniformly bullish. Indivior has a consensus “Moderate Buy” rating and an average price target of $45.17, while individual recommendations include a $53.00 buy target from Craig Hallum and a reduced—but still “overweight”—$43.00 target from Barclays. Indivior receives Moderate Buy rating
• Negative Sentiment: A law firm is investigating the proposed Supernus acquisition. Kahn Swick & Foti is reviewing whether the transaction’s price and sale process adequately protect Supernus shareholders. Under the proposed deal, Supernus investors would receive 1.5401 Indivior shares per Supernus share. The investigation may add legal and execution uncertainty to the transaction and could raise concerns about potential share issuance and dilution for Indivior investors. Supernus Pharmaceuticals investor alert

Insider Activity at Indivior

In other Indivior news, CAO Woodrow D. Anderson purchased 1,500 shares of the business’s stock in a transaction on Wednesday, August 5th. The stock was bought at an average cost of $36.28 per share, for a total transaction of $54,420.00. Following the acquisition, the chief accounting officer owned 26,138 shares of the company’s stock, valued at approximately $948,286.64. The trade was a 6.09% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Ryan Preblick sold 36,000 shares of the stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $37.70, for a total value of $1,357,200.00. Following the transaction, the chief financial officer owned 284,751 shares in the company, valued at $10,735,112.70. This trade represents a 11.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.74% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Indivior

Several large investors have recently made changes to their positions in the business. Goldman Sachs Group Inc. increased its stake in Indivior by 18.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 8,368,996 shares of the company’s stock worth $79,757,000 after buying an additional 1,299,425 shares during the period. Fuller & Thaler Asset Management Inc. increased its position in shares of Indivior by 101.0% during the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 6,371,534 shares of the company’s stock worth $228,611,000 after acquiring an additional 3,201,639 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Indivior by 57.9% during the fourth quarter. Vanguard Group Inc. now owns 5,473,891 shares of the company’s stock worth $196,403,000 after acquiring an additional 2,008,078 shares during the last quarter. State Street Corp lifted its stake in shares of Indivior by 65.5% in the fourth quarter. State Street Corp now owns 4,659,281 shares of the company’s stock worth $167,175,000 after acquiring an additional 1,844,532 shares in the last quarter. Finally, Rubric Capital Management LP lifted its stake in shares of Indivior by 31.6% in the second quarter. Rubric Capital Management LP now owns 4,647,179 shares of the company’s stock worth $68,499,000 after acquiring an additional 1,117,140 shares in the last quarter. Institutional investors and hedge funds own 60.33% of the company’s stock.

Indivior Trading Up 0.4%

Shares of NASDAQ:INDV opened at $38.82 on Friday. The company has a market capitalization of $4.58 billion, a PE ratio of 13.91 and a beta of 0.86. Indivior has a twelve month low of $21.83 and a twelve month high of $42.81. The firm has a 50 day simple moving average of $39.28 and a 200-day simple moving average of $35.64.

Indivior (NASDAQ:INDV) last posted its earnings results on Tuesday, June 30th. The company reported $5.75 EPS for the quarter. The business had revenue of $343.00 million for the quarter. Indivior had a negative return on equity of 283.11% and a net margin of 26.65%. As a group, equities research analysts predict that Indivior will post 3.66 EPS for the current fiscal year.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.